[go: up one dir, main page]

NZ193730A - 2-(pyrimidinyl amino)-1 3-diaza -2- cycloalkenes pharmaceutical compositions - Google Patents

2-(pyrimidinyl amino)-1 3-diaza -2- cycloalkenes pharmaceutical compositions

Info

Publication number
NZ193730A
NZ193730A NZ193730A NZ19373080A NZ193730A NZ 193730 A NZ193730 A NZ 193730A NZ 193730 A NZ193730 A NZ 193730A NZ 19373080 A NZ19373080 A NZ 19373080A NZ 193730 A NZ193730 A NZ 193730A
Authority
NZ
New Zealand
Prior art keywords
cycloalkenes
diaza
pharmaceutical compositions
pyrimidinyl amino
pyrimidinyl
Prior art date
Application number
NZ193730A
Inventor
A Marxer
K Eichenberger
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NZ193730A publication Critical patent/NZ193730A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ193730A 1979-05-18 1980-05-15 2-(pyrimidinyl amino)-1 3-diaza -2- cycloalkenes pharmaceutical compositions NZ193730A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH466979 1979-05-18

Publications (1)

Publication Number Publication Date
NZ193730A true NZ193730A (en) 1982-12-21

Family

ID=4280399

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ193730A NZ193730A (en) 1979-05-18 1980-05-15 2-(pyrimidinyl amino)-1 3-diaza -2- cycloalkenes pharmaceutical compositions

Country Status (21)

Country Link
EP (1) EP0019811A1 (en)
JP (1) JPS55154971A (en)
KR (1) KR830002757A (en)
AR (1) AR228256A1 (en)
AU (1) AU5848480A (en)
DD (1) DD150609A5 (en)
DK (1) DK214480A (en)
ES (1) ES8104279A1 (en)
FI (1) FI801600A (en)
GB (1) GB2052487B (en)
GR (1) GR68453B (en)
IE (1) IE49803B1 (en)
IL (1) IL60086A (en)
MA (1) MA18829A1 (en)
NO (1) NO801469L (en)
NZ (1) NZ193730A (en)
OA (1) OA06533A (en)
PL (1) PL224313A1 (en)
PT (1) PT71251A (en)
ZA (1) ZA802909B (en)
ZW (1) ZW11880A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507146A (en) * 1982-12-28 1985-03-26 Ciba-Geigy Corporation 2,4-Diamino-6-halo-5-trifluoromethylpyrimidines having herbicidal activity
DE3829469A1 (en) * 1988-08-31 1990-03-01 Bayer Ag METHOD FOR THE PRODUCTION OF SUBSTITUTED N-AZINYL-N'-SULFONYL-ISOTHIO-UREAS AND N-AZINYL-IMINODITHIOCARBONIC ACID-S, S-DIESTER AS INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION
AU9302298A (en) * 1997-09-03 1999-03-22 Eli Lilly And Company Pyrimidine derivatives
PT1317448E (en) 2000-09-15 2005-08-31 Vertex Pharma UIRAL PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CN100408573C (en) 2000-12-21 2008-08-06 沃泰克斯药物股份有限公司 Pyrazole compounds useful as protein kinase inhibitors
CA2671776C (en) * 2001-01-31 2012-12-18 H. Lundbeck A/S Gal3 receptor antagonists for the treatment of depression
WO2003076414A2 (en) 2002-03-13 2003-09-18 Euro-Celtique S.A. Aryl substituted pyrimidines and the use thereof
US7731985B2 (en) * 2002-03-15 2010-06-08 Ciba Specialty Chemicals Corporation 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces
WO2003078427A1 (en) 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azolylaminoazines as inhibitors of protein kinases
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
ATE339419T1 (en) 2002-08-02 2006-10-15 Vertex Pharma PYRAZOLE-CONTAINING COMPOSITIONS AND THEIR USE AS GSK-3 INHIBITORS
US7601718B2 (en) 2003-02-06 2009-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
AU2006279376B2 (en) 2005-08-18 2011-04-14 Vertex Pharmaceuticals Incoporated Pyrazine kinase inhibitors
EP1954277B1 (en) 2005-11-03 2017-01-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
NZ576750A (en) 2006-11-02 2012-01-12 Vertex Pharma Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
CA2673353A1 (en) 2006-12-19 2008-06-26 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
ES2374335T3 (en) 2007-03-09 2012-02-15 Vertex Pharmaceuticals Incorporated USEFUL AMINOPIRIMIDINS AS INHIBITORS OF PROTEIN KINASES.
CN101663295B (en) 2007-03-09 2014-11-05 沃泰克斯药物股份有限公司 Aminopyrimidines useful as inhibitors of protein kinases
CA2679701A1 (en) 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyridines useful as inhibitors of protein kinases
WO2008128009A2 (en) 2007-04-13 2008-10-23 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
JP5389785B2 (en) 2007-05-02 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド Thiazoles and pyrazoles useful as kinase inhibitors
EP2152696B1 (en) 2007-05-02 2014-09-24 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
WO2009018415A1 (en) 2007-07-31 2009-02-05 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
RU2011112802A (en) 2008-09-03 2012-10-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) CO-CRYSTALS AND THEIR PHARMACEUTICAL COMPOSITIONS
TWI432436B (en) * 2008-12-09 2014-04-01 Gilead Sciences Inc Modulators of toll-like receptors
KR102328682B1 (en) * 2018-08-27 2021-11-18 주식회사 대웅제약 Novel heterocyclicamine derivatives and pharmaceutical composition comprising the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE754832A (en) * 1969-08-14 1971-02-15 Beecham Group Ltd IMINAZOLINES

Also Published As

Publication number Publication date
GR68453B (en) 1981-12-30
MA18829A1 (en) 1980-12-31
FI801600A (en) 1980-11-19
IE801023L (en) 1980-11-18
EP0019811A1 (en) 1980-12-10
ZA802909B (en) 1981-05-27
OA06533A (en) 1981-07-31
IL60086A (en) 1984-03-30
NO801469L (en) 1980-11-19
AU5848480A (en) 1980-11-20
PT71251A (en) 1980-06-01
DD150609A5 (en) 1981-09-09
KR830002757A (en) 1983-05-30
AR228256A1 (en) 1983-02-15
GB2052487A (en) 1981-01-28
ES491514A0 (en) 1981-04-16
IL60086A0 (en) 1980-07-31
ZW11880A1 (en) 1980-12-17
ES8104279A1 (en) 1981-04-16
IE49803B1 (en) 1985-12-25
DK214480A (en) 1980-11-19
JPS55154971A (en) 1980-12-02
GB2052487B (en) 1983-05-11
PL224313A1 (en) 1981-02-13

Similar Documents

Publication Publication Date Title
NZ193730A (en) 2-(pyrimidinyl amino)-1 3-diaza -2- cycloalkenes pharmaceutical compositions
GB2053681B (en) Sustained release pharmaceutical composition
IL58279A0 (en) Sustained release pharmaceutical compositions
GB2053682B (en) Sustained release pharmaceutical compositions
IL60555A0 (en) Pharmaceutical compositions containing certain ureal derivatives
NZ195568A (en) Guanidine derivatives and pharmaceutical compositions
NZ192615A (en) Substituted phenyl j-substituted piperidinoalkanone derivatives and pharmaceutical compositions
AU535604B2 (en) Pharmaceutical compositions
DE3072103D1 (en) Pharmaceutical compositions containing 3-amino-pyrazoline derivatives
PH16443A (en) Substituted tetraazetricyclic compounds and their pharmaceutical compositions
GB2063874B (en) Triazole derivatives processes for the preparation thereof and pharmaceutical compositions containing them
IL70034A0 (en) Heterocyclic amino compounds,their preparation and pharmaceutical compositions containing them
IL60731A0 (en) Pharmaceutical compositions comprising propranolol
GB2056969B (en) 2 - (amino or imino) - 4 - halothiazoles
AU535605B2 (en) Pharmaceutical compositions
GB2048671B (en) Pharmaceutical composition containing dihydroegotoxine
GB2050833B (en) Pharmaceutical compositions and process for the preparation thereof
NZ193268A (en) 2-(pyrid-2-yl)-tetrahydrothiophene derivatives and pharmaceutical compositions
IL60813A0 (en) Heterocyclic compounds, their preparation and pharmaceutical compositions containing them
ZA806383B (en) Long acting pharmaceutical composition
PH16220A (en) Pyrro-lidine derivatives and pharmaceutical compositions thereof
IL62809A0 (en) Antidiarrhoeal pharmaceutical compositions comprising guanidine derivatives
NZ193533A (en) 2-isopropylamino-5-halogeno-pyrimidines pharmaceutical compositions
IL60600A (en) Pharmaceutical compositions comprising certain azolylalkenol compounds
PH15436A (en) 4-amino-2-piperidinoquinazoline derivatives and pharmaceutical compositions thereof